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Abstract 
166Ho-EDTMP is a major therapeutic agent which is widely used in bone 
palliation therapy. In this study, a 
166Ho-EDTMP complex was prepared 
successfully using an in-house synthesized EDTMP ligand and 
166HoCl3. 
Ho-166 chloride was obtained by thermal neutron irradiation (1 × 10
13 ncm
−2s
−1) 
of natural Ho(NO3)3 samples (specific activity = 3–5 GBq/mg), dissolved in 
acidic media. The radiochemical purity of 
166Ho-EDTMP was checked by ITLC 
(>99%) and stability studies in presence of human serum and final preparation 
were performed. The biodistribution of 
166Ho-EDTMP and 
166HoCl3 in wild-type 
rats was checked by scarification. SPECT imaging of 
166Ho-EDTMP was also 
performed in wild-type rats. A comparative accumulation study for 
166Ho-
EDTMP and 
166HoCl3 was performed for vital organs up to 48h. Significant bone 
accumulation (>70%) of the tracer in 48h was observed. 
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Introduction 
Bone metastases are common in the progression of various tumors such as prostate, 
breast, and lung carcinoma and they often entail an occurrence of progressive pain [1] and 424 A.  Bahrami-Samani  et al.:  
occur in many patients with solid malignant tumors [2]. Approximately 50% of patients with 
breast carcinoma and 80% of patients with prostate carcinoma develop metastatic bone 
diseases and nearly half of them experience bone pain [3]. In these patients who have 
progressive disease despite treatment, a systemic bone-avid radiopharmaceutical for 
treatment of widespread bone metastases has potential benefits [4].  
Multidentate polyaminopolyphosphonic acid ligands are known to form stable chelates with 
many metals including lanthanides. Among them, ethylenediaminetetramethylene 
phosphonic acid (EDTMP) can be envisaged as an ideal carrier moiety, for the 
development of beta emitter-based radiopharmaceuticals, for bone palliation.  
Many beta-emitters such as Sm-153, Lu-177 and Ho-166 can be produced in reasonable 
amounts using (n, gamma) reactions. Holmium-166 (Eβ
− max = 1.84 MeV, T1/2 = 26.8 hr) is 
an interesting radionuclides for targeted therapy modalities. Although it is not available in 
high specific activities, but the uni-elemental abundance makes it an accessible and 
inexpensive radionuclide and obtained specific activity is enough for radiolabeling of small 
molecules at radiopharmaceutical grades. 
Various therapeutic bone-seeking agents have been reported and used in human studies 
including 
153Sm-EDTMP (Lexidronam) [5], 
177Lu-EDTMP [6] and 
166Ho-DOTMP [7], among 
those, 
153Sm-EDTMP is the most widely used compound in the world. We have recently 
reported the production and human application of this compound in the country [8]. 
166Ho-EDTMP has been reported as a bone seeking therapeutic radiopharmaceutical for 
therapeutic applications, however its high beta energy leading to bone marrow toxicity 
makes it an interesting specific marrow ablation agent before marrow transplantation [9].  
Although the canine biodistribution and marrow toxicity of this radiopharmaceutical has 
been reported [9], no biodistribution data has been reported on rat animals.  
 
Fig 1.   Chemical formula for 
166Ho-EDTMP 
The rat animal biodistribution data is important since it is possible to estimate the absorbed 
radiation dose to human organs following intravenous administration of radio-
pharmaceutical by using the distribution data for normal rats [10]. These data are 
mandatory before any human trial studies. 
In this research, 
166Ho-EDTMP complex was prepared from in-house made starting ligand 
and biokinetic studies of the compound was investigated among vital rat organs by 
scarification studies and imaging for future human studies in the country. 
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Results and discussion 
Production and quality control of 
166Ho 
The radionuclide was prepared in a research reactor according to regular methods with a 
range of specific activity 3–5 GBq/mg for radiolabeling use, after counting the samples on 
an HPGe detector for 5 min and two major photons (5.4% of 80.68 keV and 0.9% of 
1379.94 keV) were observed. The radioisotope was dissolved in acidic media as a starting 
sample and was further diluted and evaporated for obtaining the desired pH and volume 
followed by sterile filtering (Figure 2). 
 
Fig. 2.   Gamma spectrum for 
166HoCl3 solution used in the radiolabeling  
Radiochemical impurities in the 
166Ho sample used in the radiolabeling step were checked 
by two solvent systems; A, a mixture of 10 mM DTPA solution as mobile phase on 
Whatman No.1 paper (pH.3), the free holmium cation in 
166Ho
3+ form, was chelated with 
the polydentate compound leading to the migration of the cation in 
166Ho-DTPA form to 
higher Rf (Rf.0.9), any other ionic species (such as 
166HoCl4
−, etc.) would lead to the 
observation of new radiopeaks, especially at the origin (Rf.0.0–0.1). B, a mixture of 10% 
ammonium acetate:methanol (1:1) was used as another solvent system on the Whatman 
No,.1 paper, 
166Ho
3+ remains at the origin using this system while other ionic species 
would migrate to higher Rfs. 
Radiolabeling 
To investigate the effect of EDTMP concentration on labeling yield various amounts of the 
ligand were added to fixed amount of activity. Labeling yield increased with increasing ratio 
amount (from 1:5 to 1:15) and reached above 99% in 60 minutes. 
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Fig. 3.   ITLC chromatograms of 
166HoCl3 (left) and 
166Ho-EDTMP solution (right) using 
Whatman 1 MM eluted with NH4OH: MeOH: H2O (0.2:2:4). 
Figure 3 demonstrates the radiochromatograms of free Ho-166 and radiolabeled product 
at optimized conditions in NH4OH:MeOH:H2O (0.2:2:4) solvent system. The stability of pre-
pared 
166Ho-EDTMP complex was checked up to 48 hours after preparation. The complex 
was stable in final sample and its radiochemical purity was above 99% even 48 hours after 
preparation using Whatman 1 MM eluted with NH4OH: MeOH: H2O (0.2:2:4). Stability test 
was developed for the complex in presence of human serum at 37°C using ITLC as 
mentioned above and also no change of radiochemical yield was observed for 24h. 
Biodistribution Studies 
The animals were sacrificed by CO2 asphyxiation at selected times after injection (2, 3, 4, 
24 and 48h).  
 
Fig. 4.   Percentage of injected dose per gram (ID/g %) of 
166HoCl3 in rat tissues at 2, 3, 
4, 24 and 48 h post injection 
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Dissection began by drawing blood from the aorta followed by removing heart, spleen, 
muscle, brain, bone, kidneys, liver, intestine, stomach, lungs and skin samples. The tissue 
uptakes were calculated as the percent of area under the curve of the related photo peak 
per gram of tissue (% ID/g) (Fig. 4). For 
166Ho
3+ cation, the radioactivity was mainly located 
in the liver, kidney and bone. The free cation is soluble in water and it can be excreted via 
the urinary tract. Since the metallic 
166Ho is transferred in plasma into a protein-bond form, 
the major final accumulation was shown to be in the liver. The distribution of injected dose 
in rat organs up to 7d after injection of 
166Ho-EDTMP (200 µCi/150ul) solution was 
determined. Based on these results, it was concluded that the major portion of injected 
activity of 
166Ho-EDTMP was extracted from blood circulation into bones (Figure 5). 
 
Fig. 5.   Percentage of injected dose per gram (ID/g %) of 
166Ho-EDTMP in wild-type rat 
tissues at 2, 4, 24h and 7d post injection 
 
Fig. 6.   Comparative blood activity for 
166Ho-EDTMP and 
166HoCl3 in wild-type rats 
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For better comparison of the 
166Ho-EDTMP and 
166HoCl3 species behavior, Fig. 7 
demonstrates the blood accumulation from 2 to 48h. Both compounds are washed out 
from the circulation after 48 h, although the blood wash-out mechanisms are different. 
 
Fig. 7.   Comparative bone activity for 
166Ho-EDTMP and 
166HoCl3 in wild-type rats 
Fig. 7 demonstrates the bone accumulation from 2 to 48h. 
166Ho-EDTMP is rapidly taken 
up in bones in 2h after administration and retains almost constantly up to 24 h. Instead, 
166Ho cation uptake slowly increases but never exceeds %1. 
 
Fig. 8.   Comparative kidney activity for 
166Ho-EDTMP and 
166HoCl3 in wild-type rats 
Fig. 8 demonstrates kidney activity from 2 to 48h. As mentioned earlier, 
166Ho-EDTMP is 
rapidly taken up in bones and the trapping continued in a way that almost no blood 
circulation activity as well as kidney excretion can be observed. Instead, as a water soluble 
cation most of free Ho-166 activity is washed out through kidney in 48h. 
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Fig. 9.   Comparative liver activity for 
166Ho-EDTMP and 
166HoCl3 in wild-type rats 
A major difference in liver uptake is observed for two species. Fig. 9 demonstrates liver 
accumulation from 2 to 48h. 
166Ho-EDTMP has almost no liver accumulation, which is a 
major advantage as a therapeutic radiopharmaceutical due to the possibility of increasing 
the maximum administered dose compared to other bone seeking therapeutic 
radiopharmaceuticals such as 
177Lu-EDTMP and 
153Sm-EDTMP. While Ho
3+ cation, being 
transferred by serum metalloproteins, accumulates in liver and is excreted through 
hepatobilliary excretion route, leading to the reduction in liver accumulation. 
 
Fig. 10.   Comparative spleen activity for 
166Ho-EDTMP and 
166HoCl3 in wild-type rats 
Also, a major difference in spleen uptake is observed for the two species as shown in 
Fig.10. 
166Ho-EDTMP almost is not accumulated in spleen which can be again a major 
advantage as a therapeutic radiopharmaceutical due to the possibility of increasing the 
maximum administered dose, while Ho-166 cation is present in spleen 2h post injection 
while slowly is washed out in 48h. 
Imaging study 
As shown in figure 11, the complex is majorly washed out from the circulation in first few 
hours through kidneys while is also trapped in bones especially in vertebra, cranial and 
thigh bones and insignificant activity is accumulated in other tissues. 
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Fig. 11.   Planar scintigraphic images of 
166Ho-EDTMP 4 h post injection in wild-type rat 
Experimental 
Production of 
166Ho was performed at the Tehran Research Reactor (TRR) using 
165Ho (n, 
gamma)
166Ho nuclear reaction. Natural holmium nitrate with purity of >99.99% was 
obtained from Merck Co. Whatman No. 1 was obtained from Whatman (Maidstone, UK). 
Radio-chromatography was performed by using a Bioscan AR-2000 radio TLC scanner 
instrument (Bioscan, Paris, France). A high purity germanium (HPGe) detector coupled 
with a Canberra™ (model GC1020-7500SL) multichannel analyzer and a dose calibrator 
ISOMED 1010 (Dresden, Germany) were used for counting distributed activity in rat 
organs. All other chemical reagents were purchased from Merck (Darmstadt, Germany). 
Calculations were based on the 80.6 keV peak for 
166Ho. Animal studies were performed in 
accordance with the United Kingdom Biological Council's Guidelines on the Use of Living 
Animals in Scientific Investigations, 2nd edn. Male healthy rats were purchased from 
Pasteur Institute, Tehran, Iran. 
Production and quality control of 
166HoCl3 solution 
Holmium-166 was produced by neutron irradiation of 1000 µg of natural 
165Ho(NO3)3 
(
165Ho, 99.99% from Merck Co.) according to reported procedures [11] at the Tehran 
Research Reactor at a thermal neutron flux of 4×10
13 ncm
−2s
−1. Specific activity of the 
produced 
166Ho was 5 GBq/mg after 20h of irradiation. The irradiated target was dissolved 
in 200 µl of 1.0 M HCl, to prepare 
166HoCl3 and diluted to the appropriate volume with ultra 
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pure water, to produce a stock solution. The mixture was filtered through a 0.22 µm filter 
(Millipore, Millex GV) and sent for use in the radiolabeling step. The radionuclidic purity of 
the solution was tested for the presence of other radionuclides using beta spectroscopy as 
well as HPGe spectroscopy for the detection of various interfering beta and gamma 
emitting radionuclides. The radiochemical purity of the 
166HoCl3 was checked using 2 
solvent systems for ITLC (A: 10mM DTPA pH.4 and B: ammonium acetate 10%:methanol 
(1:1)). 
Synthesis of [Ethane-1,2-diylbis(nitrilodimethanediyl)]tetrakis(phosphonic acid) 
(EDTMP) 
EDTMP was synthesized from phosphorous acid, ethylenediamine and formaldehyde in 
the presence of HCl by a modified Mannich-type reaction [12]. To the stirring mixture of 
phosphorous acid (33.66 g) and conc. HCl (33.44 g) in a vessel under N2 atmosphere, 
ethylenediamine dihydrochloride (5 g) was added drop wise and heated to reflux. Then, 
aqueous solution of formaldehyde (37 %) is added drop wise to the mixture. Refluxing (at 
100°C) is continued for 4h and the boiling suspension is then evaporated under vacuum. 
The residue was recrystallized from water/methanol mixture, m.p. 214–215˚C. IR (KBr, ν 
cm
−1): 3308, 2633, 2311, 1668, 1436, 1356. 
1H-NMR (D2O, δ ppm): 3.53 (d, J = 12.3 Hz, 
8H,-N-CH2-P=O), 3.85 (s, 4H, -N-CH2-). 
13C NMR (D2O, δ ppm): 51.63, 52.73. 
31P NMR 
(D2O, δ ppm): 10.52. 
Radiolabeling of EDTMP with 
166HoCl3 
A stock solution of EDTMP was prepared by dissolution in 1 N NaOH and diluted to the 
appropriate volume with ultra pure water, to produce a solution of 50 mg/ml. For Labeling, 
an appropriate amount of the 
166HoCl3 solution (0.1 ml, 50 mCi) containing the required 
amounts of activity was added to the desired amount of EDTMP solution (0.3 ml, 1–5 
mg/ml). The complex solution was kept at room temperature for 45 min. The final solution 
was passed through a 0.22 µm membrane filter and pH was adjusted to 7–8.5 with 0.05 M 
phosphate buffer. Sterility and apyrogenicity of final preparation were ascertained by 
routine methods. The radiochemical purity was determined using Whatman 1 MM chrom-
atography paper or ITLC-SG eluted with NH4OH: MeOH: H2O (0.2:2:4).  
Stability of 
166Ho-EDTMP in final formulation 
Stability of 
166Ho-EDTMP in final preparation was determined by storing the final solution 
at 25ºC for 2 days and performing frequent ITLC analysis to determine radiochemical 
purity using Whatman 1 MM chromatography paper or ITLC-SG eluted with NH4OH: 
MeOH: H2O (0.2:2:4).  
Stability of 
166Ho-EDTMP in presence of human serum 
Final 
166Ho-EDTMP solution (200µCi, 50 µl) was incubated in presence of freshly prepared 
human serum (300 µl) and kept at 37°C for 2 days. The stability was determined by 
performing frequent ITLC analysis using above mentioned chromatography system. 
Biodistribution studies 
The biodistribution of Ho
3+ cation as well as 
166Ho-EDTMP were determined in wild-type 
rats. For each species, 100 µL (150 µCi) of radioactive solution was injected directly to 
normal rat through their caudal vein. The animals were sacrificed by ether asyxphycation 
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at selected times after injection (2 to 48h) and percentage of injected dose in the tissues 
were determined with a γ-ray scintillation or a dose calibrator. 
Planar scintigraphy of 
166Ho-EDTMP in wild-type rats 
For imaging studies, 
166Ho-EDTMP solution (7.4 MBq, 200 μl) was injected intravenously 
to male rats through their tail veins followed by propofol-xylazine mixture injection for 
anaesthetization. The images were acquired 4h after administration of the radio-
pharmaceutical by a single-head SPECT system (Siemens) based on 80.6 keV peak (%15 
energy window). The rat-to-septa distance was 12 cm.  
Conclusion 
EDTMP ligand was synthesized in-house and the structure was determined using 
authentic spectroscopic methods followed by preparation and quality control of 
166Ho-EDTMP (radiochemical purity>99%) using optimization studies. 
166Ho-EDTMP and 
166HoCl3 preparations were administered to wild-type rats and related biodistribution data 
were checked 2 to 24 h later showing at least 70% accumulation of the drug in the bone 
tissues. Scintigraphic images were taken from wild-type rats injected with 
166Ho-EDTMP 
after 4 h and the biodistribution was shown to be consistent with scarification data. A 
comparative accumulation study for 
166Ho-EDTMP and 
166Ho
3+ was performed for vital 
organs up to 48h. 
166Ho-EDTMP is a promising agent for bone pain palliation therapy in 
skeletal metastases in human with low undesired dose to other organs in rodents. 
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